Fifth Third Bancorp increased its stake in Gilead Sciences, Inc. by 3.9% in the third quarter, bringing its total holdings to 393,565 shares valued at $43.69 million. Institutional investors now own 83.67% of the company, while insiders have recently sold a significant number of shares. Wall Street analysts have a “Moderate Buy” consensus rating for Gilead, with an average price target of $152.50, and the company recently raised its quarterly dividend to $0.82 per share.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Fifth Third Bancorp Has $43.69 Million Holdings in Gilead Sciences, Inc. $GILD
Fifth Third Bancorp increased its stake in Gilead Sciences, Inc. by 3.9% in the third quarter, bringing its total holdings to 393,565 shares valued at $43.69 million. Institutional investors now own 83.67% of the company, while insiders have recently sold a significant number of shares. Wall Street analysts have a “Moderate Buy” consensus rating for Gilead, with an average price target of $152.50, and the company recently raised its quarterly dividend to $0.82 per share.